- Home
- MGX
MGX
METAGENOMI INC
as 12-18-2024 9:54am EST
Stocks
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 70.4M | IPO Year: | 2024 |
| Target Price: | $16.67 | AVG Volume (30 days): | 4.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.61 - $12.74 | Next Earning Date: | 02-12-2025 |
| Revenue: | $55,080,000 | Revenue Growth: | 45.13% |
| Revenue Growth (this year): | 11.59% | Revenue Growth (next year): | -34.69% |
Stock Insider Trading Activity of METAGENOMI INC (MGX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wapnick Pamela | MGX | Chief Financial Officer | Dec 5 '24 | Sell | $1.86 | 1,559 | $2,899.74 | 61,492 |
Latest METAGENOMI INC News
MGX Breaking Stock News: Dive into MGX Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 days ago
Metagenomi Presents Highly Specific and Efficient Genome Editing Tools at Nature Conference “RNA at the Bench and Bedside IV”
GlobeNewswire
9 days ago
Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting
TipRanks
10 days ago
Jefferies Predicts Up to ~1000% Surge for These 2 ‘Strong Buy’ Stocks
Zacks
a month ago
What Makes Metagenomi (MGX) a New Buy Stock
Simply Wall St.
a month ago
Metagenomi Third Quarter 2024 Earnings: US$0.51 loss per share (vs US$3.33 loss in 3Q 2023)
Associated Press Finance
a month ago
Metagenomi: Q3 Earnings Snapshot
GlobeNewswire
a month ago
Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results
GlobeNewswire
a month ago
Metagenomi To Present New Preclinical Hemophilia A Data at American Society of Hematology (ASH) 66th Annual Meeting
Compare MGX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MGX METAGENOMI INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.